Differentiated thyroid carcinoma: An analysis of 249 patients undergoing therapy and aftercare at a single institution

Clinical Nuclear Medicine

Volumn 39, Issue 2, 2014, Pages 142-146

  Amin, Amr ^a   Badwey, Ahmed ^a   El Fatah, Sherif ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Department of Pediatrics   (Egypt)

Author keywords

prognosis; radioactive 131I; survival; well differentiated thyroid carcinoma

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ABLATION THERAPY; ADULT; AFTERCARE; ANALYSIS; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODEL; PUBLIC HOSPITAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SEX RATIO; THERAPY; THYROIDECTOMY;

ADULT; AGED; COHORT STUDIES; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; YOUNG ADULT;

EID: 84893006470     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000324     Document Type: Article

References (30)

1. Sciuto R, Romano L, Rea S, et al. Natural history and clinical outcome of well differentiated thyroid cancer: A retrospective analysis of 1503 patients treated at a single institution. Ann Oncol. 2009;20:1728-1735
2. Mazzaferri EL, Kloos RT. Clinical Review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463
3. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009;19:1167-1214
4. Eustatia-Rutten CF, Corssmit EP, BiermaszNR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin EndocrinolMetab. 2006;91:313-319
5. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428
6. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167
7. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997:59-64
8. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885
9. Sanders LE, Cady B. Differentiated thyroid cancer: Reexamination of risk groups and outcome of treatment. Arch Surg. 1998;133:419-425
10. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Database Report on 53,856 cases of thyroid carcinoma treated in U.S. 1985-1995. Cancer. 1998;83:2638-2648
11. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No.5 Lyon, France International Agency for Research on Cancer; 2001. Available at: Http//www-dep.iarc.fr/ globocan/globocan.htm. Accessed July 20, 2013
12. Hughes DT, Haymart MR, Miller BS, et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21:231-236
13. Morris LG, Myssiorek D. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: A population-based analysis. Am J Surg. 2010;200:454-461
14. Nixon IJ, Ganly I, Patel SG, et al. Changing trends in well differentiated thyroid carcinoma over eight decades. Int J Surg. 2012;10:618-623
15. Hughes DT, Haymart MR, Miller BS, et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21:231-236
16. Elaraj DM, Sturgeon C. Adequate surgery for papillary thyroid cancer. Surgeon. 2009;7:286-289
17. Holzer S, Reiners C, Mann K, et al. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group. Cancer. 2000;89:192-201
18. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-381
19. McConahey WM, Hay ID, Woolner LB, et al. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1986;61:978-996
20. Grebe SK, Hay ID. Thyroid cancer nodal metastases: Biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:43-63
21. Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroid- Prognostic significance of lymph node metastasis and multi-focality. Cancer. 2003;98:31-40
22. Hay ID, Grant CS, van Heerden JA, et al. Papillary thyroid microcarcinoma: A study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139-1146
23. Clarke SE. Radioiodine therapy in differentiated thyroid cancer: A nuclear medicine perspective. Clin Oncol (R Coll Radiol). 2010;2:430-437
24. Morris LF, Waxman AD, Braunstein GD. The nonimpact of thyroid stunning: Remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin Endocrinol Metab. 2001;86:3507-3511
25. Morris LF, Waxman AD, Braustein GD. Thyroid stunning. Thyroid. 2003; 13:333-340
26. Dam HQ, Kim SM, Lin HC, et al. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology. 2004;232:527-533
27. Amin A, Amin M, Badwey A. Stunning phenomenon after a radioactive iodine-131 diagnostic whole-body scan: Is it really a point of clinical consideratioñ Nucl Med Commun. 2013;34:771-776
28. Karam M, Gianoukas A, Feustel PJ, et al. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun. 2003; 24:489-495
29. Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas. J Clin Endocrinol Metab. 1997;82:3553-3562
30. Hay ID, McConahey WM, Goellner Jr. Managing patients with papillary thyroid carcinoma: Insight gained from the Mayo Clinic's experience of treating 2512 consecutive patients during 1940 trough 2000. Trans Am Clin Climatol Assoc. 2002;113:241-260.